Impact of Roflumilast on Visceral Adiposity and MetaBolic Profile in Chronic Obstructive Lung Disease: a Randomized and Controlled Trial: the RAMBO Trial.
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2014
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease; Metabolic syndrome
- Focus Pharmacodynamics
- Acronyms RAMBO
- 10 Jun 2017 Biomarkers information updated
- 10 Nov 2014 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 17 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.